The Type 1 Diabetes Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Type 1 Diabetes Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Type 1 Diabetes Market.

Some of the key takeaways from the Type 1 Diabetes Pipeline Report:

• Companies across the globe are diligently working toward developing novel Type 1 Diabetes treatment therapies with a considerable amount of success over the years. 
• Type 1 Diabetes companies working in the treatment market are Novo Nordisk, Op-T LLC, ILTOO Pharma, ImCyse, Novartis, Zealand Pharma, Eli Lilly and Company, Dompe Farmaceutici, Prevention Bio, Eledon Pharmaceuticals, Avotres, Novartis, Histogen, Vertex Pharmaceuticals, Panbela Therapeutics, Landos Biopharma, and others, are developing therapies for the Type 1 Diabetes treatment 

• Emerging Type 1 Diabetes therapies in the different phases of clinical trials are- NNC0471-0119, OPT101, ILT-101, IMCY-0098, Iscalimab, Dasiglucagon, LY3209590, Ladarixin, Teplizumab, AT-1501, AVT001, Iscalimab, Emricasan, VX-880, Eflornithine, LABP 111, and others are expected to have a significant impact on the Type 1 Diabetes market in the coming years.   
• In December 2023, Biomea Fusion, Inc. (“Biomea”), a clinical-stage biopharmaceutical firm committed to discovering and advancing innovative covalent small molecules for the treatment of genetically characterized cancers and metabolic conditions, disclosed that Health Canada has approved Biomea’s Clinical Trial Application (CTA) to investigate BMF-219 in adults diagnosed with type 1 diabetes.
• In November 2023, SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company, has commenced dosing the first participants in Australia for a HUMAN trial (Fully HUman anti-thymocyte biologic in first-in-MAN clinical study). This trial aims to explore the safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous SAB-142, a first-of-its-kind fully-human anti-thymocyte immunoglobulin developed for delaying the onset and progression of Type 1 Diabetes (T1D). The Phase 1 trial is randomized, double-blind, placebo-controlled, and includes a single-ascending dose, involving healthy volunteers as well as individuals diagnosed with Type 1 Diabetes.
• In August 2022, Eli Lilly and Company has started a Phase III clinical trial featuring a multicenter, randomized, parallel design that aims to assess the effectiveness and safety of LY3209590, a weekly basal insulin, in comparison to insulin degludec. This study focuses on participants diagnosed with Type 1 Diabetes who are under multiple daily injection therapy.
• In July 2022, Vertex Pharmaceuticals revealed a finalized agreement wherein the company will purchase ViaCyte, a privately owned biotech firm specializing in developing innovative stem cell-based therapies for treating type 1 diabetes (T1D) as a potential functional cure. The acquisition amounts to $320 million in cash.
• In June 2022, Vertex Pharmaceuticals disclosed that the U.S. Food and Drug Administration (FDA) has removed the clinical hold previously imposed on the Phase I/II clinical trial of VX-880. This investigational treatment involves stem cell-derived fully mature pancreatic islet cell replacement therapy, designed for individuals dealing with type 1 diabetes (T1D) and experiencing impaired hypoglycemia awareness along with severe hypoglycemic episodes.
• In April 2022, AVM Biotechnology secured a $1.6 million Small Business Innovation Research (SBIR) award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) to explore its small molecule, AVM0703, in reversing Type 1 diabetes (T1D). This grant will enable the company to conduct expanded research on the potential of AVM0703 both as a standalone therapy and in combination treatments to reverse recent-onset and established cases of T1D.

Type 1 Diabetes Overview

Type 1 diabetes is an autoimmune disorder where the immune system is triggered to attack and eliminate the insulin-producing cells in the pancreas. The exact cause of this autoimmune response remains unknown. Unlike type 2 diabetes, type 1 diabetes is not associated with lifestyle-related factors that can be modified.

Get a Free Sample PDF Report to know more about Type 1 Diabetes Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/type-1-diabetes-pipeline-insight

Emerging Type 1 Diabetes Drugs Under Different Phases of Clinical Development Include:

• NNC0471-0119: Novo Nordisk
• OPT101: Op-T LLC
• ILT-101: ILTOO Pharma
• IMCY-0098: ImCyse
• Iscalimab: Novartis
• Dasiglucagon: Zealand Pharma
• LY3209590: Eli Lilly and Company
• Ladarixin: Dompe Farmaceutici
• Teplizumab: Prevention Bio
• AT-1501: Eledon Pharmaceuticals
• AVT001: Avotres
• Iscalimab: Novartis
• Emricasan: Histogen
• VX-880: Vertex Pharmaceuticals
• Eflornithine: Panbela Therapeutics
• LABP 111: Landos Biopharma

Type 1 Diabetes Route of Administration

Type 1 Diabetes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Intravenous
• Subcutaneous

Type 1 Diabetes Molecule Type

Type 1 Diabetes Products have been categorized under various Molecule types, such as

• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy

Type 1 Diabetes Pipeline Therapeutics Assessment

• Type 1 Diabetes Assessment by Product Type
• Type 1 Diabetes By Stage and Product Type
• Type 1 Diabetes Assessment by Route of Administration
• Type 1 Diabetes By Stage and Route of Administration
• Type 1 Diabetes Assessment by Molecule Type
• Type 1 Diabetes by Stage and Molecule Type

DelveInsight’s Type 1 Diabetes Report covers around 100+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Type 1 Diabetes product details are provided in the report. Download the Type 1 Diabetes pipeline report to learn more about the emerging Type 1 Diabetes therapies

Some of the key companies in the Type 1 Diabetes Therapeutics Market include:

Key companies developing therapies for Type 1 Diabetes are – Vertex Pharmaceuticals, Panbela Therapeutics, Novartis, ImCyse, Tolerion, Avotres, REMD Biotherapeutics, Novo Nordisk, Eledon Pharmaceuticals, Avotres, Eli Lilly and Company, GEROPHARM, Regeneron Pharmaceuticals, Diamyd Medical, NextCell Pharma, Novartis, ViaCyte, Landos Biopharma, Zealand Pharma,  Prevention Bio, Histogen, Op-T LLC, Dompe Farmaceutici, ILTOO Pharma, Throne Biotechnologies, Oramed, Adocia, Imcyse, Janssen Biotech, Xeris Pharmaceuticals, Zealand Pharma, Jaguar Gene Therapy,  SQZ Biotech, Enthera, and others.

Type 1 Diabetes Pipeline Analysis:

The Type 1 Diabetes pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Type 1 Diabetes with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Type 1 Diabetes Treatment.
• Type 1 Diabetes key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Type 1 Diabetes Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Type 1 Diabetes market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Type 1 Diabetes drugs and therapies

Type 1 Diabetes Pipeline Market Drivers

• Rising prevalence of type-1 diabetes due to environmental and genetic factors, growing geriatric population, which is susceptible to type-1 diabetes, increasing prevalence of obesity, which is a contributing factor are some of the important factors that are fueling the Type 1 Diabetes Market.

Type 1 Diabetes Pipeline Market Barriers

• However, lack of awareness among patients regarding types of treatment available, strict approval process and side effects associated with the treatment may restrict market growth and other factors are creating obstacles in the Type 1 Diabetes Market growth.

Scope of Type 1 Diabetes Pipeline Drug Insight    

• Coverage: Global
• Key Type 1 Diabetes Companies: Novo Nordisk, Op-T LLC, ILTOO Pharma, ImCyse, Novartis, Zealand Pharma, Eli Lilly and Company, Dompe Farmaceutici, Prevention Bio, Eledon Pharmaceuticals, Avotres, Novartis, Histogen, Vertex Pharmaceuticals, Panbela Therapeutics, Landos Biopharma, and others
• Key Type 1 Diabetes Therapies: NNC0471-0119, OPT101, ILT-101, IMCY-0098, Iscalimab, Dasiglucagon, LY3209590, Ladarixin, Teplizumab, AT-1501, AVT001, Iscalimab, Emricasan, VX-880, Eflornithine, LABP 111, and others
• Type 1 Diabetes Therapeutic Assessment: Type 1 Diabetes current marketed and Type 1 Diabetes emerging therapies
• Type 1 Diabetes Market Dynamics: Type 1 Diabetes market drivers and Type 1 Diabetes market barriers 

Request for Sample PDF Report for Type 1 Diabetes Pipeline Assessment and clinical trials

Table of Contents

1. Type 1 Diabetes Report Introduction

2. Type 1 Diabetes Executive Summary

3. Type 1 Diabetes Overview

4. Type 1 Diabetes- Analytical Perspective In-depth Commercial Assessment

5. Type 1 Diabetes Pipeline Therapeutics

6. Type 1 Diabetes Late Stage Products (Phase II/III)

7. Type 1 Diabetes Mid Stage Products (Phase II)

8. Type 1 Diabetes Early Stage Products (Phase I)

9. Type 1 Diabetes Preclinical Stage Products

10. Type 1 Diabetes Therapeutics Assessment

11. Type 1 Diabetes Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Type 1 Diabetes Key Companies

14. Type 1 Diabetes Key Products

15. Type 1 Diabetes Unmet Needs

16 . Type 1 Diabetes Market Drivers and Barriers

17. Type 1 Diabetes Future Perspectives and Conclusion

18. Type 1 Diabetes Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/